ERBB2 and neoplasm: However, several factors have been identified as contributing to a poorer prognosis, including delayed treatment initiation, negative hormone receptor status, lack of HER2 overexpression, high tumor grade, advanced tumor stage at diagnosis, and metastases to sites beyond bone, such as the liver, peritoneum, or other visceral and nonvisceral organs [23].